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Background: The C1 domain of Vav1 retains a three-dimensional structure consistent with phorbol ester binding but
nevertheless does not bind.
Results: Five residues render the C1 domain less lipophilic and interfere with its binding.
Conclusion: The C1 domain of Vav1 illustrates a novel mechanism rendering the C1 domain “atypical.”
Significance: Ligands exploiting the specific amino acid differences may selectively target Vav1.
C1 domains, the recognition motif of the second messenger
diacylglycerol and of the phorbol esters, are classified as typical
(ligand-responsive) or atypical (not ligand-responsive). The C1
domain of Vav1, a guanine nucleotide exchange factor, plays a
critical role in regulation of Vav activity through stabilization of
the Dbl homology domain, which is responsible for exchange
activity of Vav. Although the C1 domain of Vav1 is classified as
atypical, it retains a binding pocket geometry homologous to
that of the typical C1 domains of PKCs. This study clarifies the
basis for its failure to bind ligands. Substituting Vav1-specific
residues into the C1b domain of PKC, we identified five crucial
residues (Glu9, Glu10, Thr11, Thr24, and Tyr26) along the rim of
the binding cleft that weaken binding potency in a cumulative
fashion. Reciprocally, replacing these incompatible residues in
the Vav1 C1 domain with the corresponding residues from
PKC C1b (C1b) conferred high potency for phorbol ester
binding. Computer modeling predicts that these unique resi-
dues in Vav1 increase the hydrophilicity of the rim of the bind-
ing pocket, impairing membrane association and thereby pre-
venting formation of the ternary C1-ligand-membrane binding
complex. The initial design of diacylglycerol-lactones to exploit
these Vav1 unique residues showed enhanced selectivity for C1
domains incorporating these residues, suggesting a strategy for
the development of ligands targeting Vav1.
The lipophilic second messenger sn-1,2-diacylglycerol
(DAG)2 plays a central role in cellular signaling. Following the
activation of many receptors, DAG is generated either through
the hydrolysis of phosphatidylinositol 4,5-bisphosphate via
phospholipase C or indirectly from phosphatidylcholine via
phospholipase D (1). Its downstream effects are mediated
through interaction with protein kinase C (PKC), RasGRP, and
five other families of effectors that possess a C1 domain recog-
nition motif (2–4). The profound involvement of PKC and
these other families of signaling proteins in proliferation, dif-
ferentiation, apoptosis, angiogenesis, and drug resistance has
emphasized the importance of these C1 domain-containing
proteins as therapeutic targets for cancer and other diseases,
andmultiple agents, e.g. bryostatin 1 or PEP005, targeted to the
C1 domains of PKC are currently in clinical trials (4, 5).
Structural studies by NMR, x-ray crystallography, and
molecular modeling have afforded substantial insights into
ligand recognition by theC1domains (6–9). These domains are
cysteine-rich zinc finger structures. The DAG-binding site is a
hydrophilic cleft formed from two pulled apart -sheets,
whereas the C1 domain surface surrounding the binding cleft is
hydrophobic. Insertion of DAG into the binding cleft serves to
complete the hydrophobic surface, and additional hydropho-
bicity is contributed by hydrophobic substituents on the DAG.
This increase in hydrophobicity upon binding promotes inser-
tion of the C1 domain into the lipid bilayer, which in turn can
drive conformational change in the overall protein structure, as
is the case with PKC, as well as promote translocation to the
membrane, changing access of the protein to interacting part-
ners. Because the lipids of the bilayer interact both with the
ligand andwith the surface of the C1 domain, great selectivity is
possible. Although DAG represents the endogenous ligand for
the C1 domains, nature has provided a diversity of high affinity
analogs such as the phorbol esters or bryostatins, and DAG-
lactones have afforded a powerful synthetic platform for prob-
ing structure-function relationships (4, 10).
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Project Z1A BC 005270 from the Intramural Research Program, NCI.
□S This article contains supplemental Figs. 1–3.
1 To whom correspondence should be addressed: National Institutes of
Health, NCI, Bldg. 37, Rm. 4048, 37 Convent Dr., MSC 4255, Bethesda MD
20892-4255. Tel.: 301-496-3189; Fax: 301-496-8709; E-mail: blumberp@
dc37a.nci.nih.gov.
2 The abbreviations used are: DAG, diacylglycerol; GEF, guanyl exchange fac-
tor; DH domain, Dbl homology domain; PH domain, pleckstrin homology
domain; PMA,phorbol 12-myristate13-acetate; PDBu,phorbol 12,13-dibu-
tyrate;MLP,molecular lipophilicity; DOG, 1,2-dioctanoyl glycerol; PS, phos-
phatidylserine; PC, phosphatidylcholine; SH, Src homology.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 16, pp. 13137–13158, April 13, 2012
Published in the U.S.A.
APRIL 13, 2012•VOLUME 287•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 13137
 at N
ational Institutes of Health Library, on Decem
ber 18, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2012/02/18/M111.320010.DC1.html 
Supplemental Material can be found at:
Initially, C1 domains were categorized into two families (11)
as follows: (i) those that boundDAG/phorbol esterwere termed
“typical,” and (ii) the more divergent members that failed to
bind were termed “atypical.” Examples of atypical C1 domains
include those of the atypical PKC isozymes (aPKC and aPKC),
c-Raf, kinase suppressor of Ras (KSR), and Vav (3, 4, 12). More
recently, it has become evident that atypical C1 domains can be
further categorized. The first subclass, represented by proteins
like c-Raf or KSR, consists of C1 domains that are grossly dis-
torted in the binding cleft geometry (e.g. deletions of several key
residues in the loops making up the binding pocket). Members
of the second subclass, in contrast, retain the binding cleft
geometry but incorporate other factors impeding ligand bind-
ing.We showed that, in the case of the atypical PKCs, a series of
three arginine residues lining the rim of the binding pocket
were able to rotate into the cleft, making it inaccessible to
ligands (13). Replacement of these arginine residues with the
corresponding residues found in the C1b domain of PKC gen-
erated high affinity ligand binding and ligand-driven mem-
brane translocation.
Recent structural studies using x-ray crystallography have
revealed a striking resemblance between the binding pocket
geometry of the C1b domain of the potent phorbol ester recep-
tor PKC and that of the protooncogeneVav1, a guanine nucle-
otide exchange factor (14–16). Although early studies on the
GEF activity of Vav1 toward small GTPases suggested a DAG/
phorbol ester-sensitive function of Vav1 (17), subsequent
ligand-binding experiments using purified recombinant Vav1
and the ultrapotent phorbol ester analog [3H]bryostatin did not
support those results (18), leading to the classification of thisC1
domain as atypical. In this study, we have sought to identify key
structural determinants in the Vav1 C1 sequence that (analo-
gous to our findings with atypical PKCs) might account for its
apparent lack of affinity for DAG and phorbol esters.
Vav1 is a versatile cellular signal transducer molecule that
plays a pivotal role in various signaling pathways. One of the
most important and best characterized functions of Vav1 is the
GEF activity toward the Rho/Rac family of small GTPases,
which are important molecular transducers in signaling cas-
cades that regulate cytoskeleton organization, cell cycle pro-
gression, gene transcription, adhesion, migration, cell growth,
and survival (19–21). In addition to their activity as exchange
factors for Rho/Rac proteins, Vav proteins can also regulate
various other cellular processes in a GEF-independent fashion,
functioning as adapter molecules to facilitate protein-protein
interactions (22). The expression of Vav1 is restricted almost
exclusively to normal cells of hematopoietic origin (23–25).
There, T-cell receptor-coupled activation of the guanine
exchange function of Vav1 leads to Rac1-induced cytoskeleton
organization, an essential step for the formation of the immu-
nological synapse and subsequent proper T-cell activation (20,
26). Vav1 further plays a crucial role inT-cell development (27).
Although less extensively investigated, recent studies have also
characterized a role of Vav1 in human cancer, especially in solid
tumors of nonhematopoietic origin (28), where the ectopic
expression of wild-type Vav1 can contribute to the develop-
ment and progression of these malignancies (29–32). It there-
fore represents an attractive therapeutic target, both for cancer
as well as for autoimmunity.
Vav1 possesses multiple structural motifs that mediate its
versatile functions in cellular signaling (Fig. 1A) (19). It contains
a Dbl homology (DH) domain, which is responsible for catalyz-
ing nucleotide exchange (33). The DH domain is flanked by an
N-terminal acidic (Ac) motif and a calponin homology (CH)
domain together with a C-terminal pleckstrin homology (PH)
domain and a C1 domain. These domains surrounding the cat-
alytic DH domain in the CH-C1 segment of the molecule reg-
ulate the exchange activity of Vav1 (28). In addition, the struc-
ture of Vav contains an SH3-SH2-SH3 cassette at the C
terminus, which links it with tyrosine phosphorylation path-
ways and mediates its activity as a scaffold protein (22).
Initial studies of Vav using site-directed mutagenesis identi-
fied the C1 domain as critical for maintaining efficient guanine
nucleotide exchange activity toward Rho/RacGTPases (34, 35).
Although this regulatory effect initially was hypothesized to
arise from direct contacts between the C1 domain and the
GTPases (36), crystallographic studies now provide a different
explanation (15, 16). An intramolecular network of contacts
between the PH-C1 unit and the DH domain helps stabilize the
conformation of a critical-helix within theDHdomain, which
is essential for the displacement of guanine nucleotide from the
GTPase. The C1 domain (together with the PH domain) thus
contributes to optimal GEF activity by restricting the confor-
mational flexibility of the DH domain, keeping it in a stable
conformation primed for efficient interaction with the Rac1
GTPase. TheC1 domain of Vav1 possesses a three-dimensional
structure very similar to that of the typical C1b domain of
PKC. Because its solvent-accessible cavity is located in the
vicinity of the -helix of DH that makes contacts with Rac1,
ligand binding to the cleft has the intriguing potential to mod-
ulate Vav1 function. Could DAG/phorbol esters or their deriv-
atives interact with this binding pocket and thereby disrupt the
enzymatic function of Vav1?
In this study we wished to characterize the ligand binding
properties of the C1 domain of Vav1.We confirmed the lack of
phorbol ester binding ofVav1.Using site-directedmutagenesis,
we identified the central structural determinants in the loops
making up the binding cleft responsible for the lack of phorbol
ester sensitivity. The C1 domain of Vav1 (together with that of
atypical PKCs) thus belongs to that subclass of atypical (nonre-
sponsive) C1 domains that retain the proper structure for
ligand binding. However, the presence of four unique hydro-
philic residues around the rim of the binding pocket disrupts
the lipophilic surface of the tip of the binding pocket and,
together with an inappropriately hydrophobic residue distal to
the tip of the C1 domain, interferes with the insertion of ligand
receptor complex into the lipid membrane, which is an essen-
tial step for stabilizing the ternary binding complex of ligand
receptor and membrane. Mutating these residues in the Vav1
C1 domain to correspond to the ones in the potent phorbol
ester receptor C1b, we demonstrated almost complete recov-
ery of binding affinity in vitro and in vivo, which confirms the
previous structural findings on the conserved binding pocket
geometry of Vav1. Our results raise the possibility that appro-
priately modified DAG/phorbol ester analogs that can specifi-
C1 Domain of Vav1
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cally target these residues might have the potential to selec-
tively bind to Vav1 C1 and to manipulate Vav1 function
through this interaction. Finally, we describe some DAG-lac-
tones that display modest selectivity for features of the Vav1-
C1-like structure.
EXPERIMENTAL PROCEDURES
Materials—[20-3H]Phorbol 12,13-dibutyrate ([3H]PDBu)
(17.2 Ci/mmol) was obtained from PerkinElmer Life Sciences.
PDBu and phorbol 12-myristate 13-acetate (PMA) were pur-
chased from LC Laboratories (Woburn, MA). Phosphatidyl-L-
serine (PS), phosphatidylcholine (PC), and 1,2-dioctanoylglyc-
erol (DOG) were from Avanti Polar Lipids (Alabaster, AL).
LNCaP human prostate cancer cells, fetal bovine serum (FBS),
RPMI 1640 medium, and L-glutamine were from the American
Type Culture Collection (Manassas, VA). Reagents used for
culturing bacteria (LBBroth, LB agar plateswith different selec-
tion antibiotics, etc.) were from K-D Medical, Inc. (Columbia,
MD). The oligonucleotide primers used for PCR cloning,
sequence analysis, and site-directedmutagenesiswere obtained
from Invitrogen.
Construction of GST-fused C1 Domains of PKC and
Vav1—The wild-type C1b domain in a pGEX-5-1 plasmid
(GE Healthcare) had previously been constructed in our labo-
ratory (48). To generate a recombinant Vav1 C1 domain fused
to glutathione S-transferase (GST) at the N terminus, PCR
amplification of the appropriate sequence was performed using
PlatinumPCRSuperMixHigh Fidelity (Invitrogen), according
to themanufacturer’s instructions. The full-length cDNAclone
of Vav1 served as template. The following oligonucleotide
primers were used in the PCR as follows: (i) forward primer
5-CGGAATTCAATGCTACAGCCAATGGGC-3 and (ii)
reverse primer 5-CGGAATTCGAAATCTTGCCCATG-
GCG-3. The DNA fragments of the PCR were purified with
QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA) and
subsequently digested with EcoRI (New England Biolabs, Bev-
erly, MA) to create adhesive ends of the C1 fragments. After an
additional step of purification with theQIAquick PCR purifica-
tion kit, the fragments were finally ligated into the GST-con-
taining pGEX-5-1 plasmid (GE Healthcare) using the EcoRI
restriction sites. Analysis of the DNA sequence of the construct
was conducted by the DNA Minicore (Center for Cancer
Research, NCI, National Institutes of Health). Verification of
the sequencing data was performed using the following soft-
ware: BioEdit Sequence Alignment Editor Version 7.0.5 and
DNA Baser Sequence Assembler Version 2.91.
Site-directedMutagenesis of theC1bDomain of PKCand the
C1 Domain of Vav1—C1 domains consisted of a conserved
50–51-amino acid sequence possessing the characteristic cys-
teine-rich motif HX12CX2CXnCX2CX4HX2CX7C, where H is
histidine, C is cysteine, X is any other amino acid, and n is 13 or
14 (Fig. 2, gray-shaded letters) (11). To facilitate comparisons
betweenC1 domains, we will refer to residues using numbering
internal to the C1 domain itself, with the N-terminal histidine
residue being labeled His1. This residue corresponds to His516
in full-length Vav1 and His231 in the C1b domain of full-length
PKC. Point mutations of the amino acid residues at positions
9, 10, 11, 22, 24, and 26 of both PKC C1b and Vav1 C1 were
introduced using the GeneTailorTM site-directed mutagenesis
system (Invitrogen) according to the manufacturer’s instruc-
tions. To generate the C1 domain mutants of PKC and Vav1,
the abovementionedwild-typeC1 constructs (PKC andVav1)
in pGEX-5-1 were used. Single, double, and triple mutations
were introduced in one step, and quadruple and quintuple
mutants were generated in a stepwise fashion using triple
mutants as templates. The presence of mutations was verified
by DNA sequencing (DNA Minicore) and analysis (BioEdit,
DNA Baser).
Construction of GFP-labeled C1 Domains of PKC and
Vav1—To generate GFP-tagged fluorescent fusion proteins for
in vivo translocation studies, pGEX-5-1 plasmids containing
recombinant C1 domain sequences from either PKC or Vav1
were digested with EcoRI (New England Biolabs). The DNA
fragments from this reaction were purified with the QIAquick
PCR purification kit (Qiagen). Finally, the C1 fragments were
ligated into the pEGFP-C2 vector (Clontech) using the EcoRI
restriction sites, and theDNA sequences of the constructs were
confirmed by sequence analysis (DNAMinicore).
Construction of Full-length Vav1 (Wild-type, Triple, and
Quintuple Mutant) Fused to GFP—The GFP-tagged wild-type
Vav1 was generated using the pENTRTM Directional TOPO
cloning kit (Invitrogen), according to the instructions described
in the manual. Briefly, PCR amplification of the appropriate
full-lengthVav1 sequencewas first carried out using Platinum
PCR SuperMix High Fidelity (Invitrogen). The cDNA clone of
Vav1 served as a template, and the following oligonucleotide
primers were applied in the PCR: (i) forward primer 5-CAC-
CGAGCTCTGGCGACAGTGC-3 and (ii) reverse primer
5-TCAGCAATATTCGGAATAGTCTTCC-3. The PCR
product was then TOPO-cloned into a pENTRTM/D-TOPO
vector, which served as an Entry clone. Next, using the LR
recombination reaction of the Gateway method (Invitrogen),
we transferred the appropriate full-length Vav1 sequence from
the Entry vector into a pcDNA-DEST53 GatewayTM destina-
tion vector (Invitrogen), which encodes anN-terminal GFP tag.
The triple (E9M/E10S/T11P) and the quintuple (E9M/E10S/
T11P/T24L/Y26K) mutants of the full-length Vav1 were gen-
erated using the GeneTailorTM site-directed mutagenesis sys-
tem (Invitrogen) described above for the C1 domain mutants.
The TOPO-Entry clone of the (full length) wild-type Vav1
served as a template for constructing the triple and quintuple
mutants in a stepwise fashion. The mutated Entry clones were
then subcloned into pcDNA-DEST53 using the above men-
tioned LR recombination reaction. The DNA sequences of the
GFP-tagged full-length constructs were verified by sequence
analysis (DNAMinicore).
Expression and Purification of GST-tagged C1 Domains from
Escherichia coli—The C1 domains of both PKC and Vav1 in
the pGEX-5-1 plasmid were transformed into BL21-AITM
One Shot chemically competent E. coli (Invitrogen). Trans-
formants were grown in LB broth medium (K-D Medical) at
37 °C until the optical density of the bacterial suspension
reached 0.6–0.8. Expression of the GST fusion proteins was
induced with 0.3 mM isopropylO-D-thiogalactopyranoside and
0.125% L-arabinose (both from Sigma) for 4 h at 37 °C. Bacterial
cells were subjected to sonication in B-PER bacterial protein
C1 Domain of Vav1
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extraction reagent, supplemented with 50mg/ml lysozyme and
2500 units/ml DNase I (all from Pierce). The expressed GST-
tagged C1 proteins were purified using a B-PER GST spin puri-
fication kit (Pierce) according to the manufacturer’s instruc-
tions. Purification efficiency was evaluated by SDS-PAGE
analysis. Protein concentration was assessed with the protein
assay kit from Bio-Rad. Purified fusion proteins were stored in
30% glycerol at80 °C.
In Vitro ([3H]PDBu Assays—To assess the affinity of the dif-
ferent C1 domains (wild-type and mutant PKC and Vav1) to
phorbol esters, purified proteins were subjected to an in vitro
[3H]PDBu binding assay, and the dissociation constants (Kd
values) of the individual C1 domains were determined. Mea-
surement of [3H]PDBu binding, using the polyethylene glycol
precipitation assay developed in our laboratory, was described
in detail previously (37). Competitive binding assays were car-
ried out to assess the affinities (Ki values) of DOG and DAG-
lactones as described in detail elsewhere (38). Triton X-100,
included in some of the assays, did not exceed 0.003%.
Translocation of GFP-labeled Proteins—LNCaP cells
(between passage numbers 5 and 20) were plated at a density of
60,000 cells/plate on Ibidi dishes (Ibidi, LLC, Verona, WI) and
subcultured at 37 °C in RPMI 1640medium supplementedwith
10% FBS and 2mM L-glutamine. After 48 h in culture, cells were
transfected with GFP-tagged recombinant constructs, using
Lipofectamine reagent and Plus reagent (both from Invitrogen)
according to the manufacturer’s protocol. Cellular expression
of fluorescent fusion proteins was examined 24 h after transfec-
tion on a Zeiss LSM 510 NLO confocal microscopy system
(Carl Zeiss, Inc., Thornwood, NY) with excitation from a
30-milliwatt argon laser tuned to 488 nm and emission col-
lected with a BP 500–530 filter. Intracellular translocation of
the GFP-labeled C1 domains upon PMA treatment was
detected sequentially after the administration of the drug.
Images were acquired every 30 s for 30 min at varying zoom
settings (1 to 3.5) using Zeiss AIM software and a 63 1.4 NA
Zeiss Plan-Apochromat oil immersion objective.
Quantitation of Confocal Images—Three regions of 4 m2
each were selected in each cell as follows: one in the cytoplasm,
one in the cell membrane, and one in the nucleus, avoiding to
the degree possible the selection of subcellular organelles such
as Golgi or the nucleoli. Mean intensities of the GFP-tagged
constructs in the selected regions were calculated using the
Zeiss AIM software for the images at the different time points;
the ratio of the intensities for membrane/cytoplasm and nucle-
us/(membrane cytoplasm) was then calculated and normal-
ized to the time 0 values. The increase in the membrane/cyto-
plasm ratio and/or the decrease in the nucleus/(membrane 
cytoplasm) ratio indicates translocation. For each series of
images presented, the mean  S.E. of the maximal transloca-
tion for all of the replicate experiments for that assay condition
is presented.
Chemistry—The DAG-lactone derivatives were synthesized
according to previously published procedures (39). Melting
points were determined on an MPA 100 OptiMelt automated
melting point system (Stanford Research Systems) or a Mel-
Temp II apparatus (Laboratory Devices, USA) and are uncor-
rected. Column chromatography was performed on a Teledyne
Isco CombiFlash Companion instrument under gradient elu-
tion conditions with RediSep disposable flash columns. Analyt-
ical TLCwas performed onAnaltechUniplates silica gel GF. 1H
NMR spectra were recorded on a Varian Unity Inova instru-
ment at 400 MHz. Spectra are referenced to the solvent in
which they were run (7.24 ppm for CDCl3). Positive ion fast
atom bombardment mass spectra (FAB-MS) were obtained on
a VG 7070E-HF double-focusing mass spectrometer operated
at an accelerating voltage of 6 kV under the control of a
MASPEC-II data system forWindows (Mass Spectrometry Ser-
vices, Ltd.). Either glycerol or 3-nitrobenzyl alcohol was used as
the sample matrix, and ionization was effected by a beam of
xenon atoms generated in a saddle-field ion gun at 8.0 0.5 kV.
Nominal mass spectra were obtained at a resolution of 1200,
and matrix-derived ions were background-subtracted during
data system processing. Full experimental details and charac-
terization have been reported previously for 6a, 6c, and 8b-e
(40). Full characterization of novel DAG-lactones designated as
compounds 6b, 8a, and 8f is described below. NMR spectra for
these compounds can be found in the supplemental material.
(E)-(2-(Hydroxymethyl)-4-((1-methyl-1H-indol-3-yl)methyl-
ene)-5-oxotetrahydrofuran-2-yl)-methyl 3-isobutyl-5-methyl-
hexanoate (6b)—1H NMR (400 MHz, CDCl3)  7.94 (t, J 2.6
Hz, 1H, Ar), 7.82 (dt, J  7.8, 0.9 Hz, 1H, Ar), 7.38 to 7.24 (m,
4H, Ar and CCH), 4.31 (Ab q, J 11.9 Hz, 2H, CH2), 3.85 (s,
3H, CH3), 3.77 (AB q, J 12.1 Hz, 2H, CH2), 3.06 (dd, J 17.2,
2.7 Hz, 1H, CH4a), 2.84 (dd, J 17.1, 2.6 Hz, 1H, CH4b), 2.22 (d,
J 6.5 Hz, 3H, CH2 and OH), 1.90 (app sept, 1H, CH), 1.63 to
1.48 (m, 2H, 2 CH), 1.17 to 0.96 (m, 4H, 2 CH2), 0.83 (dd,
J  6.6 Hz, 3H, CH3), 0.82 (dd, J  6.6 Hz, 6H, 2  CH3), and
0.78 (d, J 6.6 Hz, 3H, CH3); FAB-MS (m/z, relative intensity)
456 (MH, 97), 455 (M ., 100).
(E)-4-((5-(Hydroxymethyl)-2-oxo-5-((2-propyl-pentanoyloxy)
methyl)dihydrofuran-3(2H)-ylidene)methyl)-1-propylpyri-
dinium Bromide (8a)—1H NMR (400 MHz, CDCl3)  8.88 (d,
J 6.7Hz, 2H,Ar), 8.16 (d, J 6.6Hz, 2H,Ar), 7.66 (s, 1H,C
CH), 4.74 to 4.56 (m, 2 H, CH2), 4.33 (s, 2 H, CH2), 3.94 (d, J
12.0 Hz, 1 H, H4a), 3.92 (AB q, J 15.8 Hz, 2 H, CH2), 3.73 (d,
J 12.0 Hz, 1 H,H4b), 2.56 (v br s, 1 H, OH), 2.34 (tt, J 8.8, 5.4
Hz, 1H,CH), 2.02 (heptet, J 7.4Hz, 2H,CH2), 1.60 to 1.46 (m,
2 H, CH2), 1.43 to 1.32 (m, 2 H, CH2), 1.23 (m, 4 H, 2  CH2),
0.98 (t, J 7.4 Hz, 3 H, CH3), 0.86 (td, J 7.3, 1.6 Hz, 6 H, 2
CH3); FAB-MS (m/z, relative intensity) 404 (M, 100).
(E)-3-((5-(Hydroxymethyl)-5-((3-isobutyl-5-methylhexanoy-
loxy)methyl)-2-oxodihydro-furan-3(2H)-ylidene)methyl)-1-
pentyl-pyridinium Bromide (8f)—MP was 142–143 °C. 1H
NMR (400 MHz, CDCl3)  9.76 (s, 1 H, Ar), 8.77 (d, J 5.7 Hz,
1H, Ar), 8.72 (d, J 8.1Hz, 1H, Ar), 8.08 (irr t, 1 H, Ar), 7.39 (s,
1 H, CCH), 4.89 (br s, 2 H, CH2), 4.19 (AB q, J 12.3Hz, 2H,
CH2), 3.73 (AB q, J 12.3 Hz, 2 H, CH2), 2.88 (dd, J 18.6, 2.4
Hz, 2 H, H4ab), 2.19 (d, J  6.5 Hz, 2 H, CH2), 2.04 (br s, 2 H,
CH2), 1.88 (irr sept, 1 H, CH), 1.55 (sept, J  6.7 Hz, 2 H, 2 
CH), 1.38 to 1.35 (m, 4 H, 2  CH2), 1.15 - 0.94 (m, 4 H, 2 
CH2), 0.92 to 0.75 (m, 15 H, 5  CH3); FAB-MS (m/z, relative
intensity) 474 (M, 100).
MolecularModeling—Structures for the single- andmultiple
site mutants of the Vav1 and PKC C1 domains were built by
replacing residues while keeping their side chain  angles as
C1 Domain of Vav1
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close as possible to the conformation in the other structure. For
example, in the Vav1 crystal structure (15), residueGlu9 has the
conformation 1  74.7, 2  166.2, and 3  103.1. When
theM9Emutant of PKCwas built, the Glu residue was rotated
into the same conformation. In almost all cases, this conforma-
tion fit well into the structure, and the only exception was the
P11T mutation in PKC, which required an adjustment of
Leu20 and Phe13 to accommodate the threonine methyl group.
This constructionmethod allowed the structure of themutated
Vav1 C1 domain to be as similar as possible to the PKC C1b
domain and vice versa.
Docking of phorbol and the DAG-lactones was performed
using the software programGOLDVersion 5.0 (41). The struc-
ture of phorbol 13-acetate was extracted from its co-crystal
with the PKCC1b domain (7), and the C1 domain of Vav1 (15)
was clipped from the larger structure.Hydrogenswere added to
both protein and ligands. The binding sitewas defined by atoms
within a 10.0-Å sphere around the N atom of residue Gln27
(Gln542(B) in the full-length structure). Ligand flexibility flags
included internal hydrogen bond detection and ring corner
flipping, and the default torsion angle distributions were used.
The GoldScore scoring function was used with the default
parameter file. The genetic algorithm settings were automati-
cally optimized according to ligand flexibility with the search
efficiency set to 100%.
After docking, the structures of the DAG-lactone-triple
mutant PKC complexes were subjected to conformational
searching using MacroModel (42) to identify low energy con-
formers for the charged ligand and protein side chains. The
searches used 50 steps of systematic torsional sampling for each
rotatable bond in the DAG-lactone sn-1 and sn-2 side chains,
and in the side chains of residues Glu9, Glu10, and Thr11 in the
mutated C1 domain. Minimization of each conformer found
was done using the OPLS 2005 forcefield with octanol implicit
solvent. All atoms in the DAG-lactone and residues 9–13,
20–24, and 27 in the binding site were free to move during
minimization and the rest of the protein was held fixed.
Lipophilicity analysis was performed using the software pro-
gram VASCo (43). The molecular lipophilicity potential over
the surface of the protein was calculated in the following way.
First, an atomic logP value was assigned to each atom. The
atomic logP (AlogP) values used were those from Ghose et al.
(44), although the dictionary provided with the VASCo pro-
gram was modified to use the ionized forms of Asp, Glu, Arg,
and Lys. Next, the solvent-excluded surface was constructed
using MSMS (45), which yielded a set of surface vertices and
triangles. Finally, the lipophilicity of each surface point was cal-
culated using a Fermi-type distance function to map and
smooth the logP value of nearby underlying atoms onto the
surface, according to the formulation of Heiden et al. (46) for
large molecules. The overall molecular lipophilicity potential
(MLP) of the binding site area was calculated as the sum of the
surface point lipophilicities for those points whose closest
underlying atom lies on the solvent-accessible surface of the C1
domain in the region that inserts into the membrane and inter-
acts with phorbol (7). This included the following atoms: resi-
due 8, atoms O and C; residue 9, all atoms; residue 10, all
atoms; residue 11, all atoms; residue 12, atoms N and C; resi-
due 20, all atoms; residue 21, atom O; residue 22, atoms O, C,
C, C	, and C; residue 23, all atoms; residue 24, all atoms; and
residue 27, atoms C	, C, and N.
RESULTS
Isolated C1 Domain of Vav1 Does Not Bind Phorbol Esters,
Despite Conservation of the Appropriate Geometry of the Bind-
ing Pocket—The striking structural resemblance between the
binding cleft of Vav1 C1 and that of PKC C1b, as revealed by
recent x-ray crystallographic data (15), suggests the potential
for preserved DAG/phorbol ester responsiveness of Vav1 (Fig.
1B). To confirm the ability of the Vav1 C1 domain binding site
to accommodate phorbol ester, we extracted the phorbol
13-acetate ligand from the crystal structure of PKC C1b (7)
and docked it into the isolated C1 domain from the highest
resolutionVav1 crystal structure (15). As expected based on the
structural overlay of the binding sites, phorbol ester is predicted
to be able to bind to the Vav1 C1 domain with essentially the
same binding mode as in the PKC C1b domain (Fig. 1, C and
D). The binding site residues that form direct hydrogen bond-
ing interactions with phorbol are identical between the two C1
domains, and the pattern of intra- and intermolecular hydrogen
bonds formed by bound phorbol is preserved.
In contrast to this structural analysis andmodeling, however,
Vav1 has been shown experimentally not to interact with DAG
or phorbol esters (18). One explanation for this apparent dis-
crepancy could be that the C1 domain is located in the core of
the Vav1 structure (rather than being exposed on the surface),
and other structural domains prevent the access of ligands to
the binding cleft. Examples of such masking of C1 domains,
although in both instances not sufficient to fully block binding,
are 2-chimerin (47) and PKC (48).
To test the possibility that the C1 domain is simply masked,
we first cloned the isolated Vav1 C1 domain into a pGEX bac-
terial plasmid (Clontech) encoding a C-terminal GST tag and
assessed the binding properties of the recombinant protein in
an in vitro [3H]PDBu binding assay. Compared with the GST-
tagged PKCC1b (C1b), a high affinity phorbol ester receptor
that served as a positive control in these experiments, the Vav1
C1 showed no evidence for [3H]PDBu binding even at very high
(1–2 M) receptor concentration (data not shown) under
these conditions.
Because misfolding of the purified protein from a bacterial
expression system could be a reason for the absence of phorbol
ester binding in vitro, we examined the phorbol ester respon-
siveness of the Vav1 C1 in the intracellular environment after
eukaryotic expression. Phorbol ester causes the translocation of
typical C1 domains to cellular membranes. We expressed a
GFP-tagged Vav1 C1 in LNCaP cells, treated with phorbol
ester, and looked for subcellular redistribution using real time
confocal microcopy. The GFP-tagged C1b domain of PKC
(C1b-GFP) served as control, whose translocation dynamics
hadpreviously been extensively characterized by our laboratory
(13, 49). After the administration of 1 M PMA, C1b-GFP
showed a rapid but transient translocation into the cellular
membrane, which was followed by translocation into the
nuclear membrane (Fig. 5A). In contrast, PMA treatment failed
to induce appreciable intracellular redistribution of Vav1
C1 Domain of Vav1
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C1-GFP, in agreement with the in vitro phorbol ester binding
assays (Fig. 5B).
Multiple reports suggest that C1 domains may show some-
what differential recognition of the endogenous ligand, sn-1,2-
diacylglycerol, relative to phorbol ester (49–51). We therefore
examined the ability of dioctanoylglycerol to induce transloca-
tion of the GFP-tagged PKC C1b and Vav C1 domains (Fig.
5C). Clear translocation of the PKCC1b domain was observed
at 100MDOG, as expected (52, 53). In contrast, no significant
translocation of theVavC1domainwas observed. These results
suggest that the Vav C1 domain is unresponsive either to phor-
bol ester or to diacylglycerol.
Sequence Alignment of Vav1 C1 with Phorbol-responsive
(Typical) C1 Domains Reveals Unique Residues around the
Binding Pocket—Because the Vav1 C1 domain fails to bind
phorbol esters despite preservation of the binding cleft geome-
try, a plausible explanation is that individual residues situated
along the rim of the binding pocket or in close proximity to it
may interfere with ligand-receptor interactions by impeding
contacts between the C1 domain and the membrane lipids,
FIGURE 1. A, domain structure of the full-length Vav1. B, overlaid backbone structures of the C1 domain from PKC C1b in red (1PTR (7)), compared with the
available structures for Vav1 in green (2VRW) (15), blue (3KY9) (14), and purple (3BJI) (16). The 3KY9 and 3BJI structures are both crystallographic dimers
containing two copies of the C1 domain. Zinc atoms are rendered as CPK spheres. The backbone atoms of residues 231–274 in PKC are aligned to residues
516–559 in Vav1. The root mean square difference in these aligned atoms is 0.5 Å between the Vav1 structures and PKC, and the root mean square
difference in their full C1 domain backbones is 1.4 Å. The C1 domains of PKC and Vav1 differ in the tilt angle of the small C-terminal helix, but the
phorbol/DAG-binding sites remain essentially identical, with the same spacing between the loops forming the sides of the site, although the position of the
loops relative to the rest of the domain may be shifted slightly. C and D, docking of phorbol 13-acetate into the binding cleft of C1b and that of Vav1 C1.
C, bindingmode of phorbol 13-acetate as observed in the PKC C1b crystal structure (7). D, docked position of phorbol 13-acetate in the binding site of Vav1
(15). Hydrogen bonds are indicated by dashed lines.
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thereby disrupting the ternary binding complex, or by occlud-
ing the binding site. This situation would thus be analogous to
that of the atypical C1 domains of the aPKCs (13).
C1 domains consist of a conserved 50–51-amino acid
sequence possessing the characteristic cysteine-rich motif
HX12CX2CXnCX2CX4HX2CX7C, where H is histidine, C is cys-
teine, X is any other amino acid, and n is 13 or 14 (Fig. 2, gray-
shaded letters) (11). (In the text below, we will refer to residues
using numbering internal to the C1 domain itself, to facilitate
comparisons between C1 domains from different proteins. For
example, the N-terminal histidine residue would be labeled
His1. This residue corresponds toHis516 in full-lengthVav1 and
His231 in the C1b domain of full-length PKC.) A comprehen-
sive sequence alignment of the atypical Vav1 C1 versus typical
C1 domains highlighted several unique residues in the Vav1 C1
structure (Fig. 2). Six of these unique amino acids (Glu9, Glu10,
Thr11, Arg22, Thr24, and Tyr26) are located at or close to the tip
of the apparent binding cleft (see Fig. 3).
FIGURE 2. Amino acid sequence alignment of the atypical C1 domain of Vav1 with all the members of the typical C1 domain-containing protein
superfamily (human). Thepositions in theC1domains thatwere identified tobeunique for theVav1 structure arehighlighted in color. The individual residues
are categorized into four different groups based on their chemical properties: nonpolar (hydrophobic), polar uncharged, basic, and acidic. The color code is
depicted in the panel below the sequences. The C1 consensus sequence is highlighted in gray.
C1 Domain of Vav1
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Numerous studies indicate that hydrophobic residues
exposed to the surface along the rim of the binding pocket of
C1b (at the tips of both loops forming the cleft: residues 9–12
in the N-terminal loop and 21–24 in the C-terminal loop) facil-
itate the insertion of the top third of the binding pocket into the
membrane after ligand binding thereby stabilizing the forma-
tion of the ternary (ligand-receptor-membrane) binding com-
plex (12, 54). The N-terminal loop of the binding pocket in
Vav1 C1 contains two negatively charged Glu residues (Glu9
and Glu10) at the tip of the cleft. Although there is a moderate
variability at these positions among typical C1 domains (see Fig.
2), acidic residues are not present in any of these sequences. In
addition, the presence of Pro at position 11 is highly conserved
among phorbol-binding proteins (Fig. 2), although the experi-
mental evidence is not unambiguous regarding the role of Pro11
on binding potency (13, 55, 56). The C-terminal loop of the
binding cleft (residues 20–27) contains three unique amino
acids (Arg22, Thr24, and Tyr26). With the exception of the C1b
domains of protein kinase D isoforms, virtually all typical C1
domains contain highly lipophilic residues at the first two of
these positions (positions 22 and 24) (Fig. 3), and the important
role of Trp22 and Leu24 in the DAG/phorbol ester sensitivity of
PKC has been well documented (7, 38, 56, 57). The third can-
didate in the C-terminal loop for disrupting the phorbol ester
sensitivity of Vav1 C1 is Tyr26. Almost every phorbol-sensitive
C1 domain has a positively charged residue at this position
(Arg26, Lys26, or His26; see Fig. 2). According to the three-di-
mensional structure of C1b, positively charged residues are
exposed in themiddle third of theC1domain (“underneath” the
top third of the cleft that is buried in the membrane) and inter-
act with anionic phospholipid head groups (e.g. phosphatidyl-
serine) in the membrane, thereby further strengthening the C1
domain-membrane interaction (7). Among the basic residues
of C1b, Lys26 is situated with closest proximity to the apex of
the binding pocket (Fig. 3); therefore, it is a good candidate for
such interactions between the C1 domain and acidic phospho-
lipids. Tyr26 in Vav1 C1, being a noncharged residue, would
have a reduced capacity to interact with acidic phospholipids.
Characterization of the Phorbol Ester Sensitivity of PKC C1b
Mutants Possessing Vav1-C1-likeMutations
Single Site C1b Mutants Demonstrated Only Moderate
Decreases in the Binding Affinity for PDBu in Vitro—To deter-
mine the possible effect of the above unique residues on the
ligand sensitivity of Vav1C1, our initial approachwas to use the
C1b domain of PKC as a template and to mutate individual
residues to the corresponding residues of Vav1-C1 at these
positions (site 9, 10, 11, 22, 24, and 26). We first generated six
single site C1b mutants fused to GST and determined their
apparent [3H]PDBu binding affinities (Table 1). Five out of six
single site mutations (M9E/S10E/P11T/L24T/K26Y) caused a
moderate decrease in the binding affinity of C1b for
[3H]PDBu, whereas the W22R mutation had no effect on its
potency for the ligand.
Replacement of the highly hydrophobic Met9 residue with a
negatively charged hydrophilic Glu9 resulted in an 11-fold
reduction in the binding affinity for [3H]PDBu (Kd  2.11 
0.11 nM). The introduction of Glu10 to replace the polar but
uncharged Ser10 caused a 9.2-fold loss of measurable binding
(Kd  1.77  0.06 nM), comparable with that of the previous
mutation. These results suggest that, although the presence of
an acidic residue at these sites decreases the binding potency by
1 order of magnitude, it does not abrogate the interactions
FIGURE 3. Locations of themutated residues in the C1 domains. The locations of the residues subjected to mutation (A) in the PKC C1b domain (7) along
the two loops forming the phorbol-binding site and the corresponding residues (B) in the Vav1 C1 domain (15) are shown.
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within the ternary binding complex, because both theM9E and
S10Emutants still retain a considerable potency for [3H]PDBu.
The P11T mutant showed a 9.1-fold weaker affinity for
[3H]PDBu (Kd 1.76 0.21 nM) compared with the wild-type
C1b. Although the replacement of the nonpolar Pro residue
with a polar Thr decreased the binding affinity (to the same
degree as the glutamate mutations M9E and S10E), the rela-
tively high residual potency of the P11T mutant argues that a
threonine residue at this site is compatible with a significantly
high level of phorbol ester affinity. This result is in good agree-
ment with previous studies, which demonstrated that the
replacement of Pro11 with arginine caused only a weak (4.4-
fold) reduction in the binding potency of C1b for [3H]PDBu
(13), comparable with the results obtained with the P11T
mutant in this study.
The mutation at Trp22 had no effect on the phorbol ester
binding of C1b. TheKd value of theW22Rmutant (0.16 0.02
nM) remained essentially on the same level as that of the wild-
type C1b (0.193 0.005 nM). This result agrees with our pre-
vious findings, which showed only a very weak reduction in the
phorbol ester binding potency of C1b after the introduction of
Lys into this site (38). Therefore, we can conclude that,
although almost every typical C1 domain (with the exception of
somePKD isoforms) conserves a hydrophobic residue at site 22,
the presence of positively charged residues at this site generally
seems to be fully compatiblewith a high level of binding affinity,
at least for phorbol esters. In contrast with the results for PDBu
binding, binding of DAG has been described as being highly
dependent on the presence of Trp22 (38, 57, 58).
Mutations at Leu24 (L24T) and Lys26 (K26Y) caused a similar
decrease in binding affinity as did the other consequential
mutations. Although our sequence alignment found that a
polar residue (like Thr24) essentially never occurs at position 24
for typical C1 domains (suggesting a crucial structural role for
nonpolar residues), the influence of a polar residue at position
24 is thus apparently limited. Likewise, whereas the presence of
a basic residue at site 26 is an almost uniform characteristic of
typical C1 domains (with chimaerins being the sole exceptions),
mutating the Lys26 of C1b to a noncharged Tyr residue (to
correspond to Vav1 C1) had only a modest effect.
We conclude that none of the unique residues (identified by
our sequence alignment) in the Vav1 C1 structure by itself
account for the lack of phorbol ester affinity. Rather, our results
suggest that the loss of binding reflects the cumulative effect of
multiple changes, each with more modest effect.
Combination of the Five Vav1-like Mutations in C1b
Resulted in a Dramatic Reduction in the Binding Affinity for
PDBu in Vitro—To explore the combined effect of the above
mutations on ligand sensitivity, we generated double, triple,
and quintuple C1b mutants (see Table 1) that contained mul-
tiple Vav1 C1-like residues in the same construct. Because the
single site mutation at Trp22 had no effect on the binding affin-
ity of C1b for phorbol esters, we omitted this mutation from
further study. As shown in Table 1, the double mutations at the
apex of both loops of the binding cleft caused a considerable
loss of binding affinity, with the L24T/K26Y mutant (C-termi-
nal loop) showing a somewhat more pronounced reduction in
its binding potency compared with that of the M9E/S10E
mutant at the N-terminal loop. Except in the case of mutants
including P11T, the reductions in binding affinities of the com-
bined mutants were greater than the product of the reductions
of the individual mutants. These results argue that the com-
bined effect of multiple mutations on the binding affinity can-
not be readily predicted based merely on the affinity results of
single site mutants. Finally, the combined introduction of all
five mutations (M9E/S10E/P11T/L24T/K26Y) into C1b abol-
ished detectable binding affinity. Under our in vitro assay con-
ditions, this would imply a decrease of more than 5 orders of
magnitude in binding potency (i.e. themutated C1bwould not
be able to bind [3H]PDBu in the 10 M range).
We conclude that the five unique residuesGlu9, Glu10, Thr11,
Thr24, and Tyr26 in the binding pocket of Vav1 are together
sufficient to account for the lack of detectable phorbol ester
binding activity by the Vav1 C1 domain. Studies described
belowwill address the question of whether other residues in the
Vav1 C1 domain further contribute to the lack of measurable
phorbol ester binding.
The translocation experiments had provided no support for
the suggestion that the Vav1 C1 domain could respond to dia-
cylglycerol, despite its lack of response to phorbol ester.
Althoughwe could notmeasure binding of diacylglycerol to the
Vav1 C1 domain directly, we could approach this question by
examining the binding of DOG to several of our multiple site
C1bmutants that still retained some affinity for phorbol ester.
The multiple site C1b mutants in fact showed substantially
decreased affinities for DOG, although the decreases in affinity
were somewhat less than seen for [3H]PDBu (Table 2).
Five Vav1-like Mutations in C1b Modestly Influence the
Phospholipid Selectivity of the C1 Domain—As described
above, the five unique residues would be predicted to influence
the interaction of the C1 domain with the phospholipid bilayer.
For example, Sossin and co-workers (53) described a role for
positively charged residues at positions 9, 10, and 26 of PKCApl
II from Aplysia in the recognition of phosphatidylserine and
phosphatidic acid. We therefore examined the binding of
[3H]PDBu to wild-type PKC C1b and the double mutants
TABLE 1
In vitro binding affinities of [3H]PDBu for WT C1b and the single and
multiple site C1bmutants
Individual C1 domains were fusedwithGST and expressed in a bacterial system and
isolated, and the binding of [3H]PDBu to the individual C1 domains was
measured. Values represent the mean S.E. (n 3 independent experi-
ments). NA means no activity.
Receptor (PKC C1b) Kd Relative to WT
nM
Wild type 0.193 0.005 1
Single mutants
M9E 2.11 0.11 10.9
S10E 1.77 0.06 9.1
P11T 1.76 0.21 9.1
W22R 0.16 0.02 0.8
L24T 2.63 0.15 13.6
K26Y 0.97 0.10 5.0
Multiple mutants
M9E/S10E 50.5 2.1 261
M9E/S10E/P11T 186.1 6.0 963
L24T/K26Y 96 18 499
M9E/S10E/P11T/
L24T/K26Y
NA NA
C1 Domain of Vav1
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M9E/S10E and L24T/K26Y in the presence of PS/PC phospho-
lipid mixtures with 100 g/ml total lipid and variable propor-
tions of PS (Fig. 4). Both pairs ofmutations reduced the depend-
ence on phosphatidylserine for [3H]PDBu binding, as was most
evident in lipid mixtures of 0–5% PS. In addition, the L24T/
K26Y double mutant showed optimal binding at 20% PS,
whereas the C1b domain and the M9E/S10E double mutant
bound best at 50–100% PS.
To better explore the basis for this difference in lipid selec-
tivity, we determined the binding affinities for [3H]PDBu of
C1b and the two double mutants in the 5:95 PS/PC lipid mix-
ture. All three C1 domain showed reduced affinity but the loss
of affinity was modestly greater in the case of the C1b wild-
type (Table 3). We conclude that the mutations causing the
C1b to more resemble Vav1 indeed influenced its lipid recog-
nition. The change in lipid environment did not increase the
binding affinity, however, arguing that the specific phospho-
lipid composition was not responsible for the lack of the bind-
ing of the Vav1 C1 domain in vitro.
As a further control, we examined the ability of the wild-type
Vav1 C1 domain to bind [3H]PDBu in the presence of the 5:95
PS/PC lipid mixture. The experiments again failed to reveal
binding of appreciable affinity, although under our conditions
we cannot exclude affinities in the millimolar range (data not
shown).
In Vivo Membrane Translocation Kinetics of GFP-tagged
Multiple Site Mutants of C1b Mirror Their Binding Activities
Measured in Vitro—To explore how these mutations affect the
phorbol ester response of C1b in the intracellular environ-
ment, we investigated the plasma membrane translocation
dynamics of theGFP-tagged C1bmutants in LNCaP cells after
the administration of various concentrations (0.1–10 M) of
PMA. Representative images for selected experiments are illus-
trated, but we also include quantitation for the multiple repli-
cates under each experimental condition. In response to 1 M
PMA, the WT C1b translocated rapidly to the plasma mem-
brane, with loss from both the cytosol and nucleus (Fig. 5A).
The redistribution of the signal from the cytosol into the plasma
membrane was complete within 5–7 min after the application
of PMA (data not shown), whereas the nuclear redistribution
culminated after 10–15min. Subsequently, the fluorescent sig-
nal began to return to the cytosol within 15–20 min and was
clearly detectable at 30 min. The translocation dynamics of the
wild-type molecule showed a clear dependence on the concen-
tration of PMA. Reducing the concentration to 0.1 M delayed
the rapidity of translocation. Fig. 5A shows weak signs of
plasma membrane translocation at 2–5 min, which became
complete only after 15 min (in clear contrast to the 1 M PMA
treatment). However, increasing the concentration of the PMA
treatment accelerated the translocation process. A very rapid
and complete plasmamembrane translocation of theWT C1b
with 10 M PMA is visible within 2 min after activation, along
with signs of nuclear membrane translocation (data not
shown). Moreover, the return of the fluorescent signal into the
cytosol began earlier than for the 1 M treatment (at 10–15
min). The results obtained with the C1b demonstrate that the
translocation pattern was indicative of the concentration of
PMA in this concentration range. Likewise, the C1b domain
translocated quickly after addition of DOG (100 M) mainly to
internal membranes with some plasma membrane transloca-
tion (Fig. 5B).
The double mutant M9E/S10E, which displayed a 260-fold
reduction of potency compared with the wild-type C1b in the
above in vitro experiments, showed amuch weaker response to
0.1 and 1 M PMA (Fig. 5A and data not shown for 0.1 M
PMA). Increasing the concentration of the PMA to 10 M
resulted in a much faster response of M9E/S10E (Fig. 5A), sim-
ilar in pattern to that obtained with the wild-type form after the
application of 0.1MPMA as follows: (a) signs of plasmamem-
brane translocation detected as early as 2 min; (b) more pro-
nounced although incomplete translocation into the plasma
membrane at later time points; and (c) redistribution of M9E/
S10E from the nucleus within 20–30 min. The other double
mutant (L24T/K26Y) displayed a very similar translocation
pattern to M9E/S10E in response to PMA treatment. These
results are consistent with the 260-fold (for M9E/S10E) and
498-fold (for L24T/K26Y) reductions in potency compared
with WT C1b in vitro.
FIGURE4.Bindingof [3H]PDBu towild-typeC1band thedoublemutants
C1b M9E/S10E and C1b L24T/K26Y was measured in the presence of
phospholipid mixtures of PS/PC in the indicated proportions at 100
g/ml of total phospholipid. Values were expressed relative to binding in
the presence of 100%PS. Data are themean of triplicate experiments. Bars,
S.E.
TABLE 2
In vitro binding affinities of DOG for WT C1b and multiple site C1b
mutants
Individual C1 domains were fusedwithGST and expressed in a bacterial system and
isolated, and the binding of DOG to the individual C1 domains was measured by
competition with [3H]PDBu. Values represent the mean S.E. (n 3 independent
experiments).
Receptor
(PKC C1b) Ki
Relative
to WT
nM
Wild type 22.3 1.6 1
M9E/S10E 1337 247 60
M9E/S10E/P11T 11,700 3800 524
L24T/K26Y 3870 810 174
TABLE 3
In vitro binding affinities of [3H]PDBu for WT C1b and multiple site
C1bmutants
Binding of [3H]PDBuwasmeasured in the presence of a phospholipidmix-
ture of 5% PS, 95% PC (100 g/ml total phospholipid). Values represent
the mean S.E. (n 3 independent experiments.
Receptor (PKC C1b) Ki
nM
Wild-type C1b 1.51 0.25
C1b M9E/S10E 180 30
C1b L24T/K26Y 360 140
C1 Domain of Vav1
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The triple mutant (M9E/S10E/P11T) showed a more severe
loss of binding potency for [3H]PDBu in vitro, compared with
that of the double mutants (963-fold reduction). In agreement
with this, the triple mutant (M9E/S10E/P11T) showed a hardly
detectable response to PMA at 1M (Fig. 5A). However, similar
to the doublemutants it did display a fairly quick response to 10
M PMA (Fig. 5A), with detectable plasma membrane translo-
cation as early as 2 min, and a partial translocation out of the
interior of the nucleus at later time points (20–30 min). This
confirms the severe reduction (960-fold) of binding potency
that was measured in vitro but also demonstrates that, similar
to the in vitro findings, a certain degree of phorbol ester
response remained detectable for the triple mutant in vivo as
well. In contrast to the double and triple mutants, we could not
detect any signs of intracellular redistribution of the quintuple
mutant (M9E/S10E/P11T/L24T/K26Y) in response to PMA at
this concentration range (Fig. 5A). Increasing the concentra-
tion of PMA above 10 M resulted in severe disorganization
of the cellular architecture, so we were unable to explore possible
translocation at higher PMA concentrations. We conclude that
our in vivo translocation studies support the important contribu-
tionof the five unique residues along the rimof the bindingpocket
to the lack of phorbol ester affinity of Vav1 C1.
Characterization of the Phorbol Ester Sensitivity of Vav1 C1
Mutants Containing C1b-like “Back”Mutations
Introduction of Five C1b-likeMutations into the Sequence of
Vav1 C1 Resulted in an Almost Complete Recovery of Phorbol
Ester Sensitivity, Both inVitro and inVivo—Although the above
studies argue that the five unique residues we identified in the
Vav C1 domain could be sufficient to account for the loss of
Vav1 phorbol ester binding, it is possible that other residues in
the Vav C1 domain independently might also interfere with
binding. To address this question, we generated a quintuple
back-mutant of Vav1 C1 (E9M/E10S/T11P/T24L/Y26K),
which contained the corresponding residues of C1b at posi-
tions 9, 10, 11, 24, and 26 in the binding cleft but retained all the
other native residues of Vav1.We evaluated the in vitro binding
affinity of the GST-tagged quintuple back-mutant for
[3H]PDBu. Strikingly, it bound [3H]PDBu and did so with high
affinity (Kd  1.05  0.15 nM (Table 4), compared with Kd 
0.193  0.005 nM for the wild-type C1b (Table 1)). We con-
clude that the five residues identified are the primary basis for
the failure of Vav1 to bind phorbol ester. An additional residue
or residues must make a further minor contribution to affinity,
accounting for the remaining 5-fold affinity difference.
The in vivo translocation experiments with the GFP-tagged
quintuple back-mutant (E9M/E10S/T11P/T24L/Y26K) con-
firmed the phorbol ester responsiveness. In contrast to the
translocation was in response to A. PKC C1b wild-type and the multiple site
mutants were treatedwith PMA (0.1–10M). B, PKCd C1bwild-type and Vav1
C1wild-type treatedwith 100MDOG. C, Vav1 C1wild-type and themultiple
site mutants treated with PMA (0.1–10 M). Each panel represents images
typical of three to six independent experiments. Maximal extents of translo-
cation, measured as the increase in the ratio of plasma membrane/cytoplas-
mic staining (designatedmembrane) or as thedecrease in the ratioof nuclear/
(cytoplasm and plasma membrane) staining (designated nuclear) were
quantitated for all replicates and presented as the mean S.E.
FIGURE 5. Translocation pattern of the GFP-tagged wild-type C1b and
themultiple sitemutants of C1b in living LNCaP cells after PMAorDOG
treatment. Cells expressing the wild-type C1b or the various multiple site
mutants of C1b were treated with PMA or DOG. The translocation pattern
was examined by confocal microscopy as a function of time. Pattern of
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wild-type Vav1 C1, which showed no response to phorbol ester
orDOG treatment, the quintuple back-mutant displayed trans-
location in response to as little as 0.1MPMA (Fig. 5C), reflect-
ing high phorbol ester sensitivity comparable with that
obtained with WT C1b. In addition, the translocation kinet-
ics/pattern of the quintuple Vav1 back-mutant, like that of the
wild-type C1b, showed a dose-dependent change on PMA
concentration, i.e. increasing the concentration of PMA accel-
erated the process of plasma membrane translocation and that
of nuclear translocation.
Collectively, the almost complete recovery of the binding
affinity of Vav1 C1 E9M/E10S/T11P/T24L/Y26K (consistent
with the results obtained with C1b mutants) further support
previous crystallographic results (15) and our docking results,
which demonstrate a retained binding cleft geometry for Vav1
C1 and a conserved binding pocket for ligand interaction. The
reason for the lack of ligand affinity is the presence of these five
residues at the rim of the binding pocket which presumably
hinder the association of the C1 domain with the cellularmem-
brane, thereby destabilizing the ternary binding complex and
reducing the potency for phorbol esters.
Introduction of Double-, Triple-, and Quadruple C1b-like
Mutations into the Sequence of Vav1 C1 Further Dissects the
Role of the Individual Residues in the LigandAffinity of Vav1C1—
To further explore whether all five residues actually contribute
to the lack of binding potency in theWTVav1C1, we generated
double, triple, and quadruple back-mutants of Vav1 C1 (see
Table 4). Introducing two back mutations into the N-terminal
(Vav1 C1 E9M/E10S) or the C-terminal (T24L/Y26K) loop of
the apparent binding cleft of Vav1 C1 was insufficient to
recover the phorbol ester response of the molecule. In vitro
assays could not detect any measurable [3H]PDBu binding
(Table 4), and no translocation could be observed in vivo after
10 M PMA treatment (data not shown). Back-mutating the
three residues in the N-terminal loop (E9M/E10S/T11P) con-
ferred only a very weak binding potency (Kd 7330 490 nM)
on the triple back-mutant (Table 4), which could only be
detected in vitro but not with translocation assays (data not
shown). These results suggest that the presence of compatible
residues at the tip of both loops is needed for appropriate bind-
ing affinity. They stand in partial contrast to the previous find-
ings with the double (M9E/S10E; L24T/K26Y) and triple (M9E/
S10E/P11T)mutants of C1b (Table 1 andFig. 5A), which failed
to completely abolish the binding potency of the C1bmutants.
Because the difference lies in the presence of other residues in
the PKC C1b domain versus Vav1, it emphasizes both that
these residues make a difference and that the effects of the
combination of residues are not simply additive.
Next, using quadruple back-mutants of Vav1 C1 (listed in
Table 4), we analyzed the individual contribution of each of the
five residues in the backbone structure of the Vav1 C1 to the
lack of ligand binding, for comparison with their contributions
in the context of the PKC C1 domain. In this set of experi-
ments, the quintuple back-mutant of Vav1 C1 (E9M/E10S/
T11P/T24L/Y26K) can be considered analogous to the WT
C1b (both containing the appropriate residues for potent
ligand binding) and the quadruple back-mutants of Vav1 C1
(see Table 4) analogous to the single site mutants of C1b (see
Table 1) of our previous experiment (all possessing one residue
less than required for the most potent binding cleft geometry).
(For brevity we will refer to the quadruple back-mutants by
mentioning the residue that they lack, compared with the quin-
tuple Vav1 C1 mutant, with an antecedent negative sign; see
Table 4 for details.) The binding constants (Kd values) of three
out of five quadruple mutants showed a nearly uniform reduc-
tion in potency. Themutants (E10S), (T24L), and (Y26K)
all displayed a decrease of 25–35-fold in potency for [3H]PDBu,
compared with the binding affinity of the quintuple Vav1 C1
mutant (Table 4). This is consistent with the uniform reduction
(5–13-fold; see Table 1) in the binding affinity of the single site
C1b mutants compared with their wild-type counterpart,
although the degree of reduction is slightly higher than in the
case of C1b mutants. However, in contrast to the single site
mutants of C1b at site 9 and 11 (C1b M9E and C1b P11T),
their analogous quadruple Vav1 C1 mutants (Vav1 C1 E9M
andT11P, respectively) displayed a more severe reduction in
their binding potencies (929-fold for E9M and 189-fold for
T11P compared with the quintuple Vav1 C1 mutant). This
suggests a more significant role for Met9 and Pro11 in ligand
binding within the backbone structure of Vav1 C1, as opposed
to that observed in the context of C1b. In agreement with the
in vitro results, the in vivo translocation experiments with the
quadruple back-mutants confirmed that Met9 and Pro11 had a
larger effect on phorbol ester response than did the other three
residues (Ser10, Leu24, and Lys26). As seen in Fig. 6, the applica-
tion of 10M PMA induced a quick plasmamembrane translo-
TABLE 4
Kd values of [
3H]PDBu for binding to wild-type Vav1 C1 and different multiple site Vav1 C1mutants
GST-tagged C1 domains were expressed in a bacterial system and isolated, and the binding potencies for [3H]PDBuwere determined. Values represent themean
S.E. (n 3 independent experiments). NA means no activity.
Receptor (Vav1 C1) Kd
Relative to PKC
C1bWT
Relative to Vav1 C1
E9M/E10S/T11P/T24L/Y26K
nM
Wild type NA NA NA
E9M/E10S NA NA NA
T24L/Y26K NA NA NA
E9M/E10S/T11P 7330 490 38,000 6985
E9M/E10S/T11P/T24L/Y26K 1.05 0.14 5.4 1
Quadruple mutants
E10S/T11P/T24L/Y26K (E9M) 980 120 5052 929
E9M/T11P/T24L/Y26K (E10S) 26.4 2.4 137 25.1
E9M/E10S/T24L/Y26K (T11P) 198 18 1026 189
E9M/E10S/T11P/Y26K (T24L) 34.9 3.9 181 33.2
E9M/E10S/T11P/T24L (Y26K) 31.4 5.1 163 29.9
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cation in the case of theE10S,T24L, andY26K mutants.
In addition, although the redistribution from the cytosol into
the plasma membrane was not complete, we could observe a
fairly strong fluorescent signal in the membrane within 15 min
after the administration of the drug, and an almost complete
translocation out of the interior of the nucleus. In contrast, the
E9M mutant displayed only a weak translocation into the
plasma membrane that had much slower kinetics than that of
the previous threemutants andwas limited to certain regions of
the plasma membrane. Moreover, the nuclear translocation
was also limited for this mutant. The translocation of the
T11P mutant in response to PMA displayed an intermediate
pattern compared with that of the three more potent mutants
(E10S, T24L, and Y26K) and E9M, which showed the
weakest response. Although a fairly quick initial plasma mem-
brane translocation could be detected, the redistribution from
the cytosol was only partial, and the fluorescent signal was
absent from certain regions of the plasma membrane. In addi-
tion, translocation out of the nucleus was quite limited.
Collectively, the results obtained with the quadruple Vav1 C1
mutants emphasize theprominent contributionofMet9 andPro11
to the binding affinity of the quintuple Vav1 C1 mutant (E9M/
E10S/T11P/T24L/Y26K) for phorbol esters, which in turn indi-
cates that Glu9 andThr11make amore significant contribution to
the reduction of the binding potency of the wild-type Vav1 C1,
compared with the other three residues (Glu10, Thr24, and Tyr26).
Rationalizing the Phorbol Binding andMembrane
Translocation Behavior of PKC and Vav1Mutants in Terms of
Molecular Lipophilicity
A plausible interpretation of the role played by the five
unique residues was that the lack of phorbol ester responsive-
ness in Vav1 was due to the inability of its C1 domain to asso-
ciate with and insert into the membrane, forming the ternary
protein ligand lipid complex that is required for successful
ligand binding. To better assess this model, we developed a
method of calculating and quantifying the differences in lipo-
philicity between our various C1 domain mutants. We were
FIGURE 6. Translocation pattern of the GFP-tagged quintuple and quadruple Vav1 C1 back-mutants in living LNCaP cells after PMA treatment. Cells
expressing the quintuple back-mutant Vav1 C1 E9M/E10S/T11P/T24L/Y26K and the indicated quadruple back-mutants were treated with 10 M PMA. Cells
were imaged by confocal microscopy, and images captured at the indicated times are shown. Each panel represents a typical image of three to five indepen-
dent experiments. Maximal extents of translocation, measured as the increase in the ratio of plasmamembrane/cytoplasmic staining (designatedmembrane)
or as the decrease in the ratio of nuclear/(cytoplasm and plasmamembrane) staining (designated nuclear) were quantitated for all replicates and presented as
the mean S.E.
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interested in seeing how the membrane affinity of a C1 domain
mutant correlatedwith itsKd value for PDBu and itsmembrane
translocation behavior.
The standard metric for quantifying the hydrophobicity or
lipophilicity of small molecules is logP, a measure of the parti-
tion coefficient between octanol and water. However, logP is a
whole-molecule number and as such is not particularly useful
for characterizingmacromolecules, where the lipophilicitymay
vary significantly between different parts of the structure. This
is especially true for peripheral membrane proteins such as the
typical (DAG/phorbol-responsive) C1 domains. Computa-
tional methods for estimating logP generally involve summing
up the fractional lipophilicities of individual atoms or small
fragments. These values are based on regression analysis from
libraries of small molecules with carefully measured experi-
mental values of logP (44). The concept of an MLP is an exten-
sion of these types of calculations that can be applied to larger
molecules such as proteins. The MLP is analogous to an elec-
trostatic potential around a protein based on the partial charges
on individual atoms. Each atom is assigned an atomic logP
(AlogP) value, and these values are then projected outward
from the underlying atoms onto the solvent-accessible molec-
ular surface. In otherwords, the lipophilicity value at each point
on the surface is a smoothed distance-dependent function of
the fractional logP values of all nearby atoms (59). An algorithm
for this calculation has been implemented in the software pro-
gramVASCo (43), which also includes a plugin for PyMOL (60)
for surface visualization.
We built model structures for each of the single andmultiple
site mutants of the Vav1 and PKC C1 domains and calculated
the molecular lipophilicity potentials over their surfaces using
VASCo. Fig. 7A shows a view of these surfaces, for the wild-
type, triple, and quintuple mutant structures, seen from an ori-
entation looking down into the binding site. The surfaces are
colored according to the value of the lipophilicity at each point.
The binding site surfaces for all the C1 domains are mainly of
intermediate lipophilicity (green colored) with patches of
stronger hydrophobicity (red color). Wild-type PKC is more
lipophilic than wild-type Vav1, due mainly to the presence of
Met9, Pro11, and Leu24. Wild-type Vav1 has only one patch of
strong hydrophobicity, at Leu20. However, the presence of Glu9
and Glu10 does not introduce any strong hydrophilic character
(blue color) to the binding site, as the polarity of the carboxylate
groups is smoothed out by surrounding nonpolar atoms. Simi-
larly, Arg22 in Vav1 does not appear significantly more hydro-
philic than Trp22 in PKC, because its guanidinium headgroup
lies folded down below the surface of the binding site, and it is
themethylene groups in the side chain that formpart of the rim.
Thus, Fig. 7A offers a qualitative explanation of the relatively
small effects of individual mutations and suggests that it is the
overall lipophilicity of the top third of theC1domain that drives
its ability to respond to phorbol.
To look at the correlation between molecular lipophilicity
and phorbol sensitivity, the sum of theMLP over the surface of
the binding site for each of the PKCC1b and Vav1 C1 domain
constructs was extracted from theVASCo output and is plotted
in Fig. 7, B and C, along with the [3H]PDBu binding affinities
and a color-coded summary of translocation behavior. Trans-
location assays were not performed for all of the PKC C1b
singlemutants, but in those cases good phorbol binding affinity
was assumed to imply a normal translocation response. At the
two ends of the scale, it is clear that C1 domains with high
lipophilicity on the binding site surface bind PDBu in vitrowith
good affinity and translocate in vivo in response to PMA; con-
versely, C1 domains with low binding site lipophilicity do nei-
ther of these things. Approximate cutoffs can be drawn to say
that C1 domains with binding siteMLP values0.0 will be fully
phorbol-responsive, C1 domains with binding site MLP val-
ues 	 10.0 will not be phorbol-responsive, and C1 domains
with binding site MLP values between 0.0 and10.0 will prob-
ably retain some phorbol-binding ability butmay ormay not be
fully responsive.
The quintuplemutatedVav1C1 domain remains slightly less
lipophilic than thewild-type PKCC1bdomain, and conversely
quintuple mutated PKC is still more lipophilic than wild-type
Vav. This indicates that the five mutations do not completely
manage to “convert” one C1 domain into the other, in terms of
the overall lipophilicity, but they come quite close. The largest
numerical part of the difference is due to Trp versus Arg at
position 22, but as we have shown earlier, this substitution does
not affect phorbol binding at all.
The K26Y and S10E single mutants of PKC and the corre-
sponding Vav1 quadruple mutants E10S and Y26K show
the smallest changes in lipophilicity relative to wild-type PKC
and quintuplemutant Vav1. Thus, it is not surprising that these
mutants retain strong phorbol binding affinities. In fact, Glu at
position 10 is actually more lipophilic than Ser because of the
methylene units in the side chain. As discussed above, position
26 is not directly involved in the binding site surface, because it
is located below the binding site in the middle third of the C1
domain. However, Tyr at this position does slightly increase the
lipophilicity of the surface near residues 8 and 9.
The other PKC singlemutants andVav1 quadruplemutants
have intermediate lipophilicities, in roughly the same range as
the double and triple mutants of PKC and the triple mutant of
Vav1. In this intermediate range, phorbol binding affinities and
translocation dynamics do not necessarily correlate linearly
with the numerical MLP values. For example, the molecular
lipophilicity calculations do not explain the stronger-than-ex-
pected negative effect of double mutations in PKC (or the
triple mutation in Vav1, which is structurally equivalent to the
PKC L24T/K26Y double mutant). An alternative interpreta-
tion of the data is that the Vav1 quadruple T24L mutant as
well as the PKC M9E and L24T mutants show much better
phorbol responsiveness than would be expected based on their
binding site lipophilicities. The difference betweenThr and Leu
at residue 24 gives a significant difference in the binding site
MLP, yet this substitution on its own produces only a modest
effect on phorbol binding, and the Vav1 T24L mutant can
translocate rapidly. It is interesting that this mutant does show
an altered subcellular distribution, with a concentration in the
nucleus, before phorbol is applied to the cells (Fig. 6). These
results suggest that for C1 domains with intermediate lipophi-
licities, the ability to respond to phorbol may depend on the
precise locations of hydrophobic and hydrophilic residues in
C1 Domain of Vav1
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FIGURE 7. A, modeling of solvent-accessible surfaces of the C1 domain constructs. The surfaces of C1 domains are colored according to the molecular
lipophilicity potential, from blue (hydrophilic) to red (lipophilic). Panel a,wild-type PKC C1b. Panel b, PKC C1bM9E/S10E/P11T. Panel c, PKC C1bM9E/S10E/
P11T/L24T/K26Y.Panel d,Vav1C1E9M/E10S/T11P/T24L/Y26K.Panel e,Vav1C1E9M/E10S/T11P.Panel f,wild-typeVav1.Note that residue26 is not visible in this
orientation, which is looking down into the phorbol-binding site from the top of the domain. B and C, quantification of the overall molecular lipophilicity
potential (MLP) of themembrane-interacting andphorbol-binding site areaof theC1bandVav1C1domains (see “Experimental Procedures” for details on the
MLP calculations). B,MLP (colored bars) for PKCC1bmutant constructs. Thewild-type structure is on the left, and themutants are arranged frommost to least
lipophilic. C,MLP for Vav1 C1 domainmutant constructs. The wild-type structure is on the left, andmutants are ordered from least tomost lipophilic. The bars
are colored green for C1 domains that translocate normally in response to PMA, light green for domainswhich translocatemore slowly, yellow for domains that
showed partial or limited translocation behavior, and red for domains that did not translocate at all or showed negligible translocation. The binding affinity to
[3H]PDBu for each C1 domain is plotted on the right-hand axis on a log scale (blue points and line).
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the binding site, and the balance of lipophilicity across the C1
domain.
QuintupleMutated C1 Domain of Vav1 Retains Its Phorbol
Ester Sensitivity in the Context of the Full-lengthMolecule and
Is Capable of Targeting the Protein to the Cellular Membrane
in Response to Ligand
To elucidatewhether the binding cleft of theVav1C1 is capa-
ble of interacting with phorbol esters in the context of the full-
length molecule, we generated a full-length quintuple Vav1
back-mutant, which contained the same five back-mutations
(E9M/E10S/T11P/T24L/Y26K) in its C1 domain as the quintu-
ple mutant of the isolated Vav1 C1. We speculated that if the
binding cleft is not occluded by other domains in the full-length
molecule, the introduction of the five crucial residues into the
C1 domain would confer phorbol ester sensitivity on the full-
length Vav1 protein as well. We cloned the genes of the quin-
tuple full-length mutant (Vav1 E9M/E10S/T11P/T24L/Y26K)
along with its wild-type counterpart into a vector encoding an
N-terminal GFP fusion tag, and we subjected them to in vivo
translocation assays. (Because of technical difficulties with pro-
ducing sufficient amounts of purified protein, we were unable
to conduct in vitro binding experiments on full-length Vav1.)
Fig. 8 shows that, similar to the findings with the isolated Vav1
C1, the full-length quintuple back-mutant of Vav1 (Vav1 E9M/
E10S/T11P/T24L/Y26K) possessed affinity for phorbol esters,
because the application of 10 M PMA resulted in the translo-
cation of the protein into the plasma membrane. In clear con-
trast with the quintuple Vav1 mutant, the wild-type and the
triple mutant (Vav1 E9M/E10S/T11P) of the full-length Vav1
failed to redistribute from the cytosol into the plasma mem-
brane (similar to the results obtained with the isolated Vav1
C1). These results demonstrate unambiguously that replacing
the residues of Vav1 at positions 9–11, 24, and 26 (of its C1
domain) with C1b-like amino acids confers phorbol ester sen-
sitivity on the full-length Vav1 protein as well. In the context of
the interaction of the C1 domain of Vav1 with the DH and PH
domains (Fig. 9A), it can be seen that the three residues on the
N-terminal loop point out into solvent. Thus, although mutat-
ing these three residues can provide some detectable binding
affinity for phorbol, their mutation would appear not to disrupt
the quaternary packing of the C1 domain. In contrast, both of
the mutations in the C-terminal loop would affect its interac-
tions with the rest of the protein. The T24L mutation clashes
with residue Val373 in helix6 of the DHdomain, and the Y26K
mutation introduces an unfavorable electrostatic interaction
between the lysine and either residueArg402 or residue Lys429 in
the PH domain. This suggests that the N-terminal loop muta-
tions act to increase the lipophilicity of theC1domain formem-
brane binding and the C-terminal loop mutations act to loosen
or disrupt the packing of the C1 domain as well as increasing
lipophilicity. Both sets of mutations are required for respon-
siveness to phorbol.
Themodeling has a further implication. Because of the prox-
imity of the C-terminal loop of the C1 domain of Vav1 to the6
helix of the DH domain, a prediction is that an appropriately
bulky ligand binding to the C1 domain should disrupt interac-
tion with the DH domain (Fig. 9B). Because the C1 domain
interaction is required to stabilize the GEF activity of the DH
domain, such a ligand might be expected to function as a Vav1
inhibitor.
Comparison of the Binding Affinities of Novel DAG-lactones
Designed to Target the Structure of Vav1 C1
The modeling and site-directed mutagenesis results
shown above suggested that eliminating the charged Glu res-
idues in the N-terminal loop is necessary (but not sufficient)
for restoring phorbol sensitivity to Vav1.We theorized that a
ligand bearing a positive charge might similarly “cancel out”
the membrane binding penalty imposed on the C1 domain
FIGURE 8. Translocation pattern of the full-length versions of GFP-tagged wild-type Vav1 and the triple and quintuple Vav1 back-mutants in living
LNCaPcells after PMAtreatment.Cells expressing the full-lengthproteins of thewild-typeVav1, of the triple back-mutant, andof thequintuple back-mutant
were imaged by confocal microscopy after the application of 10 M PMA. Images captured at the indicated times are shown. Each panel represents a typical
image of four to six independent experiments. Maximal extents of translocation, measured as the increase in the ratio of plasma membrane/cytoplasmic
staining (designated “membrane”) were quantitated for all replicates and presented as the mean S.E.
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by the negatively charged residues in the N-terminal loop. It
is believed that ions in salt-bridged pairs have a reduced
desolvation penalty or increased lipophilicity for interaction
with the bilayer (61). Such a strategy is used pharmaceuti-
cally to improve the intestinal absorption of charged or ion-
izable drugs (62).
To test this theory we used a series of DAG-lactones. DAG-
lactones have proven to provide a high affinity template readily
amenable to the introduction of structural variation to probe
the nature of ligand-C1 domain interactions (10). The chemical
structures of the specific derivatives examined are illustrated in
Fig. 10A. The various DAG-lactones possess positively charged
guanidinium (6c) and pyridinium (8a–f) moieties at the sn-2
side chain position. In addition, we included compounds with
neutral pyridine (6a) and methylindole (6b) side chains for
comparison.
FIGURE 9. A,mutations of the C1 domain of Vav1 in the context of adjacent regions (the DH and PH domains) of the full-length protein (15). The C1 domain is
colored green, and the DH and PH domains are colored gray. Mutations in the C1 domain are overlaid with thewild-type residues and colored yellow. Residues
in the DH and PH domains that conflict withmutations are labeled. Amagenta arrowmarks the steric clash between residue Val373 and a Leu at position 24 in
the C1 domain. B, phorbol 13-acetate docked into the C1 domain of Vav1 (2VRW (15), colored green), in the context of its interactionswith the DHdomain. The
other lower resolution crystal structures of Vav1 are aligned as in Fig. 1B and colored blue (3KY9) (14) and purple (3BJI) (16). Although the orientation of the DH
helix differs slightly depending onwhether or not the CH domain is present and/or the exchange factor Rac1 is bound (15, 16), in all structures residues in the
3and6helices of theDHdomain arepositioned to clashwith a ligand in theC1domainbinding site. The residueswith the strongest steric clashes tophorbol
are shown and labeled.
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FIGURE 10. A, chemical structure of the positively charged diacylglycerol-lactone derivatives. B, relative binding affinities for [3H]PDBu and compounds 6c and
8f of the double and triple mutants of C1b. The ratios of the binding affinities of the indicated compounds for the mutant C1b domain relative to the
wild-type C1b domain are plotted. For [3H]PDBu, the binding affinity was measured as the Kd value; for compounds 6c and 8f, it represents the Ki value, as
indicated in Table 5. C and D, charged DAG-lactones 6c (C) and 8f (D) docked into the C1 domain of PKC C1b M9E/S10E/P11T. Electrostatic interactions are
indicated by dashed lines.
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To test the relative selectivity of these compounds for the
Vav1 C1 structure, we performed in vitro competition assays
with [3H]PDBu using the double (M9E/S10E) and triple (M9E/
S10E/P11T) mutants of C1b. These mutants retained appre-
ciable binding affinities for [3H]PDBu (which is a prerequisite of
our detection of reduced binding in competition assays), how-
ever, they displayed marked reduction of binding potency as a
result of incorporating Vav1 C1-like residues in their structure.
They nevertheless provide useful surrogates as we begin to
explore strategies for targeting the specific structural features
of Vav1.
As shown in the 1st column of Table 5, introduction of a
positive charge into the DAG-lactone yielded compounds that
were 83-fold (6c) to 30,000-fold (8a) weaker in affinity for the
wild-type PKC C1b domain than was [3H]PDBu. However,
when these charged compounds were assayed against the dou-
ble and triplemutants, the decrease in their binding affinity was
significantly less than the decrease in binding affinity seen with
neutral PDBu and the neutral DAG-lactones. The binding of
[3H]PDBu for the double and triple mutants was reduced 261-
and 963-fold, respectively, compared with that for the WT
C1b. The binding affinities of the neutral DAG-lactones 6a
and 6b to the doublemutant were also reduced 45- and 82-fold,
respectively, consistent with the loss of binding that we had
observed for DOG (Table 2). In contrast, the affinity of the
pyridinium-containing lactone 8f for these mutants decreased
only 5-fold in the case of the double mutant (M9E/S10E) and
5.5-fold in the case of the triple mutant (M9E/S10E/P11T).
Similarly, the affinity of the guanidinium-containing lactone 6c
decreased only 12- and 17-fold, respectively. The relative bind-
ing affinities of these two charged compounds and [3H]PDBu to
the double and triple mutants versus the wild-type C1b
domain are depicted in Fig. 10B.
Within the pyridinium-containing DAG-lactones, the
greater affinity of 8f for the double mutant, relative to its less
active isomer 8c, suggests that the exact orientation of the pos-
itive charge in the pyridinium ring is important for effective
neutralization. Comparing compound 8c, with a 5-carbon
chain on the pyridinium ring, to the less potent compounds 8b
(3-carbon chain) and 8d (9-carbon chain) suggests that the
exact length of this alkyl chain is also important. The presence
and extent of branching in the alkyl groups on either the sn-1 or
the sn-2 side chains also affect their binding affinities. We have
shown previously that subtle differences in the chemical struc-
ture of the side chains on the DAG-lactone template can pro-
duce widely varying biological responses (63), due in part to
differences in the degree of penetration of charged DAG-lac-
tones into the membrane (40). These results suggest that the
3-pyridyl and guanidyl series of compounds could be explored
further to optimize their alkyl substituents and examine their
biological effects against charged C1 domains in vivo.
To rationalize and visualize our results, we docked the high-
est affinity charged DAG-lactones 6c and 8f into the triple
(M9E/S10E/P11T) mutant structure of C1b. Because docking
holds the receptor structure fixed, we followed it with a confor-
mational search of the ligand and the charged binding site side
chains to allow them to form favorable interactions. As shown
in Fig. 10,C andD, Glu10 can easily forma salt bridge to both the
charged nitrogen in the pyridinium group of DAG-lactone 8f
and the guanidinium group of DAG-lactone 6c. The additional
alkyl chain on the sn-2 pyridinium ring of compound 8f pro-
vides greater hydrophobic coverage over the top surface of the
C1 domain, which could promote the insertion of this complex
into the bilayer, and explain its slightly better affinity.
These results illustrate that the DAG-lactone template is in
principle structurally capable of forming ion-pair interactions
with charged residues in the C1 domain binding site. Although
these compounds represent only an early stage in the design of
agents targeting the C1 domain of Vav1, they support the con-
cept that appropriate interaction with the unique negatively
charged residues at positions 9 and 10 may represent one ele-
ment in the strategy.
DISCUSSION
C1 domain-containing proteins have been classified into two
major groups based on ligand responsiveness (11). Typical C1
domains bind DAG/phorbol esters, whereas atypical C1
domains do not. Previous findings of our laboratory with the
atypical PKCs (aPKCs) indicated that the family of atypical C1
domains could be further divided (13). c-Raf andKSR exemplify
atypical C1 domains with a structurally distorted binding
pocket that is not compatible with ligand interactions, whereas
the aPKCs have a C1 domain that retains a compatible binding
cleft geometry but possesses other characteristics that interfere
with efficient ligand interactions, namely the four arginine res-
idues lining the rim of the binding pocket can fold into the cleft,
effectively competing with ligand. Vav1 is another member of
the subclass of atypical C1 domains with compatible binding
pocket geometry and the potential to interact with DAG ana-
logs. In this study, we showed that the basis for the lack of
activity of Vav1 appears to be different from that in the case of
the aPKCs. Modeling emphasizes that the rim of the binding
cleft of Vav1 displays enhanced hydrophilicity, interfering with
membrane insertion and stabilization of the ternary binding
complex. We identified four hydrophilic residues in Vav1 C1
(Glu9, Glu10, Thr11, and Thr24) that drive its lack of binding.
Beyond the hydrophobic cap, C1 domains have an annulus of
charged residues that interact with negatively charged phos-
pholipid headgroups. In Vav1, we identified an additional resi-
TABLE 5
Binding of different DAG-lactone derivatives to C1b double and tri-
ple mutants
The inhibitory dissociation constants (Ki) of C1M9E/S10E and of C1M9E/S10E/
P11T for the DAG lactones were defined in the presence of [3H]PDBu. Values
represent themean S.E. (n 3 independent experiments). NAmeans no activity;
ND means not determined.
Compound
name
Receptor PKC
C1b wild type
Receptor PKC
C1b M9E/S10E
Receptor PKC
C1b M9E/S10E/P11T
Ki Ki Ki
nM nM nM
[3H]PDBu 0.193 0.005 50.5 2.1 186.1 6.0
6a 10.0 1.5 451 70 ND
6b 0.66 0.6 54.0 4.1 ND
6c 16.1 1.7 191 15 285 28
8a 5810 420 NA ND
8b 714 97 6690 550 ND
8c 215 19 1760 140 ND
8d 792 67 11680 840 ND
8e 25.2 1.3 1061 27 ND
8f 27.7 6.2 137 15 151 36
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due (Tyr26) in this annular region that further contributes to the
inhibition of binding.
A striking finding, for Vav1, as well as for the aPKCs, was that
in neither case did a critical residue cause a major structural
change in the binding pocket that abrogated ligand affinity.
Rather, lack of binding represented the cumulative effect of the
otherwise modest impact of multiple individual residues on
binding potency, a mechanism of “death by a thousand cuts.”
Our experimental approaches using forward and back
mutagenesis afforded somewhat different conclusions about
the importance of different residues. The C1b single site
mutants indicated an almost uniform contribution for each of
the five unique residues to the lack of ligand binding. However,
the findings with the Vav1C1 quadruplemutants (analogous to
C1bmutants in this setting) suggested amore robust effect for
each residue in the lack of ligand binding, and in addition they
revealed a more prominent impact for the Glu9 and Pro11 resi-
dues on binding potency. These differences, together with the
lack of additivity of the effects upon multiple changes in resi-
dues, provide a reminder that the context, i.e. the influence of
the other residues in the C1 domain, on the overall behavior
cannot be ignored. It also is consistent with our calculations
that the overall lipophilicity of the C1b is greater than that of
the Vav1 C1 domain, even after introduction of the mutated
residues.
Because of the structural similarities between the C1
domains of Vav1, Vav2, and Vav3, we speculate that factors
similar to those that interfere with the phorbol ester binding of
Vav1 might also apply in the cases of Vav2 and Vav3. Likewise,
Vav orthologs have been described in both Caenorhabditis
elegans and in Drosophila melanogaster (64, 65). Evaluation of
their behavior should further extend our understanding of C1
domain structure-function relationships.Anumber of otherC1
domains reported either to be weakly sensitive or not sensitive
to phorbol esters or diacylglycerol, such as those of RasGRP2
(66) or PKC
C1a (67, 68), afford a further opportunity to probe
factors influencing C1 domain ligand interactions. As with
Vav1, such structural differences in turn may afford the oppor-
tunity for the design of specific ligands exploiting these struc-
tural differences.
Vav1 represents a therapeutic target rich in potential appli-
cations. Vav1 is an essential regulator of leukocyte functions,
including T-cell activation and development, B-cell function,
induction of the killing function of Natural Killer cells, and the
migration and phagocytic activity of macrophages (22).
Although mutated versions of Vav1 have never been described
in human cancer, the aberrant expression of thewild-type Vav1
in several malignancies (e.g.melanoblastoma, pancreatic ductal
adenocarcinoma) suggests that it can play a pivotal role in
tumorigenesis and tumor progression (28, 29). Finally, the actin
cytoskeleton remodeling mediated by Vav1 through the Rho/
Rac1 family of small GTPases may contribute to the increased
invasive and metastatic potential of neoplastic cells (69).
The C1 domain has been shown to play a critical role in the
enzymatic function of Vav1 (34). Our current understanding,
from the x-ray crystallographic analysis of Rapley et al. (15), is
that there is a complex network of intramolecular contacts
between the C1 (and the PH) domain and the DH domain,
which help to restrict the flexibility of a crucial 6 helix in the
DH domain, thereby stabilizing it in a conformation that facil-
itates maximal exchange activity. The solvent-exposed cavity
formed from the apparent binding pocket of the C1 domain lies
in the vicinity of these intimate interactions. In fact, the authors
identified that Arg22, Thr24, and Phe25 (using the C1 domain
terminology) form very significant connections with the resi-
dues situated at the 6-helix of DH domain within this DH-C1
interface. These residues are located at the C-terminal loop of
the binding pocket of C1. Our findings reveal that the Vav1 C1
domain indeed possesses the potential to accommodate DAG/
phorbol esters. Although the presence of unique residues along
the binding cleft renders the molecule noncompatible with
membrane insertion, these residues provide a unique opportu-
nity for drug design, engineering specific contacts. Given the
high selectivity of phorbol esters, DAG-lactones, and related
compounds forC1domains (10), the combination of this chem-
istry with further features exploiting the specific features of a
class of atypical C1 domain targets such as those of Vav should
provide great specificity. Our current understandingmakes the
strong prediction that such ligand binding, by disrupting theC1
domain-DH domain interactions, should inhibit the exchange
activity of Vav.
Although these possibilities remain speculative, in this study
we tested a series of diacylglycerol-lactones to begin to explore
this concept. A strategy adopted by theMarquez and Blumberg
group (10) for efficient synthesis of ligands that interact with
the binding pockets of the C1 domain-containing proteins
(most notably PKCs) was the cyclization of the structure of the
low affinity endogenous ligandDAG to generate the conforma-
tionally constrained DAG-lactones, which with optimization
can achieve affinities approaching high pM. Using this
approach, we have previously developed the novel DAG-lac-
tone 130C037, which displayed marked selectivity among the
recombinant C1a and C1b domains of PKC and PKC, as well
as substantial selectivity for the guanyl exchange factor RasGRP
relative to PKC (49). We have further shown the potential of
combinatorial chemistry for identification of diacylglycerol-
lactones with selectivity for any of a variety of biological end
points (63). Although the diacylglycerol-lactones described
here were only of moderate nanomolar affinity, several showed
markedly enhanced selectivity, compared with the prototypical
ligand PDBu, for the C1b domain containing several of the
Vav1-specific residues, which we used as a surrogate for the
wild-type Vav1 C1 structure. These DAG-lactone derivatives
contained a positively charged side chain that had the potential
to interact with the negatively charged glutamic acid residues.
Although such compounds provide proof of principle, it should
be emphasized that they represent only a first step.
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